Plague vaccine injectable - DynPort/USAMRIID

Drug Profile

Plague vaccine injectable - DynPort/USAMRIID

Alternative Names: Recombinant F1V plague vaccine - Dynport Vaccine Company; rF1V vaccine

Latest Information Update: 17 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator United States Army Medical Research Institute of Infectious Diseases
  • Developer DynPort Vaccine Company
  • Class Plague vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Yersinia infections
  • New Molecular Entity No

Highest Development Phases

  • Phase II Yersinia infections

Most Recent Events

  • 17 Mar 2017 Plague vaccine injectable is still in phase II trials for prevention of Yersinia infections in USA
  • 08 Mar 2017 Plague vaccine injectable - DynPort/USAMRIID receives Orphan Drug status for Yersinia infections in USA
  • 22 Aug 2012 DynPort completes a phase II trial in Healthy volunteers in US (NCT01122784)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top